BioCentury | Sep 26, 2019
Financial News

ZielBio raises $25M series A to advance two new cancer targets

...Fund to advance a functional proteomics platform that has generated two first-in-class preclinical mAbs targeting CSP1...
...investors. It is now using the series A funding to bring its lead program against CSP1...
...According to Kelly, who serves as president and CSO of ZielBio, her team unexpectedly discovered CSP1’s...
BioCentury | Apr 23, 2019
Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
BioCentury | Jan 11, 2019
Clinical News

CereSpir's itanapraced reduces neurotoxicity in PD model

CereSpir Inc. (New York, N.Y.) reported on Dec. 10 that lead product itanapraced (CSP-1103) reduced neurotoxicity in a mouse model of Parkinson’s disease and in cultured neurons from the model. The company said the data...
BioCentury | Oct 27, 2017
Clinical News

GSK begins Phase II of malaria vaccine candidate

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) began a Phase II trial of intramuscular RTS,S vaccine (Mosquirix, GSK257049) to vaccinate against malaria infection. The open-label, U.S. trial will evaluate adult and pediatric formulations of the vaccine in 160...
BioCentury | Apr 6, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers Blood levels of immune cell markers and antibodies could help predict protective responses to Plasmodium CSP -based malaria vaccines. A cohort of 46 healthy volunteers received one of two malaria vaccine regimens...
BioCentury | Jan 12, 2017
Company News

GeneCentric, Bristol-Myers Squibb deal

Bristol-Myers Squibb and GeneCentric partnered to explore the feasibility of using GeneCentric’s Cancer Subtype Platform (CSP) to identify translational biomarkers for cancer drug Opdivo nivolumab for use in clinical trials. The pharma will provide undisclosed...
BioCentury | Jan 6, 2017
Clinical News

GAP3KO vaccine: Ph I data

An open-label, U.S. Phase I trial in 10 healthy volunteers showed that GAP3KO administered via the bite of 150-200 GAP3KO-infected mosquitoes under controlled conditions prevented malaria infection in all subjects. Specifically, all 10 subjects developed...
BioCentury | Oct 19, 2015
Company News

Oberland Capital Management LLC, Agenus deal

Agenus sold its royalty stream on sales of shingles vaccine HZ/su and malaria vaccine RTS,S ( Mosquirix ) to Oberland for a $100 million note. Agenus will receive an additional $15 million note if FDA approves HZ/su,...
BioCentury | Jul 27, 2015
Clinical News

RTS regulatory update

EMA’s CHMP recommended approval of Mosquirix from GlaxoSmithKline for active immunization of children ages 6 weeks to 17 months against malaria caused by Plasmodium falciparum and against hepatitis B. The malaria vaccine targeting the circumsporozoite...
BioCentury | Jul 25, 2015
Company News

CHMP backs GSK's malaria vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received a positive opinion from EMA's CHMP for its Mosquirix malaria vaccine in children aged 6 weeks to 17 months -- moving the product a step closer to becoming the first...
Items per page:
1 - 10 of 42